H. Pylori Profile

Half the world carries Helicobacter pylori (H. pylori) in their stomach, yet most never know it. A standard test tells you whether the bacterium is present. This panel goes further: it identifies the specific genetic features that make some strains far more likely to cause ulcers and stomach cancer, and it reveals whether common antibiotics will actually work against your strain. That distinction matters, because treatment fails in roughly one out of every five to three out of every ten people who receive standard triple therapy, often because the bacterium was resistant to the prescribed antibiotic from the start.

The combination of detection, virulence profiling, and resistance testing in a single stool sample gives you and your clinician the information needed to act on an H. pylori diagnosis intelligently rather than guessing at treatment.

What This Panel Reveals

This panel answers three distinct clinical questions from one stool sample. First, it confirms whether H. pylori is present using DNA based detection (called PCR, or polymerase chain reaction), which is more sensitive than standard stool antigen testing. Second, it profiles the strain's virulence, the biological features that determine how aggressively the bacterium damages your stomach lining. Third, it tests for genetic mutations linked to antibiotic resistance, so treatment can target the bacterium's actual vulnerabilities.

Virulence: Not All Strains Are Created Equal

H. pylori strains vary enormously in the harm they cause. Some sit quietly in the stomach lining for decades without producing symptoms. Others carry a molecular toolkit that drives inflammation, destroys the protective mucus barrier, and promotes the cellular changes that lead to ulcers and cancer. The virulence markers in this panel identify which toolkit your strain carries.

The two most studied virulence genes are cagA and vacA. A protein called CagA (cytotoxin associated gene A) is injected directly into stomach lining cells by the bacterium, reprogramming them toward inflammation and abnormal growth. A meta-analysis of studies involving H. pylori positive individuals found that people carrying cagA positive strains had roughly double the odds of developing gastric cancer compared to those with cagA negative strains. The vacA gene encodes a toxin that punches holes in stomach lining cells. Its potency depends on which version of the gene the strain carries.

The remaining virulence markers fill in the picture. The babA gene produces a protein that helps the bacterium latch tightly onto stomach cells, and babA positive strains are more frequently found in people with peptic ulcers and gastric cancer. The oipA gene drives production of a protein that triggers a strong inflammatory response. The dupA gene (duodenal ulcer promoting gene A) has been linked to higher rates of duodenal ulcers. Together, the virB and virD genes encode parts of the molecular syringe (type IV secretion system) that delivers CagA into your cells.

Resistance: Why Standard Treatment Often Fails

Standard H. pylori treatment relies on combinations of two or three antibiotics taken with an acid suppressing medication. The most commonly prescribed first line regimen historically includes clarithromycin, but global resistance to this antibiotic has risen sharply. A systematic review and meta-analysis covering data from 65 countries found that pooled clarithromycin resistance in the Americas was approximately 10%, while in Europe it exceeded 18% and in parts of Southeast Asia it surpassed 25%. In some US metropolitan areas, resistance rates now exceed 20%.

When H. pylori is resistant to clarithromycin, standard triple therapy (a proton pump inhibitor plus clarithromycin plus amoxicillin) succeeds in fewer than 50% of cases, compared to roughly 85 to 90% when the strain is susceptible. Fluoroquinolone resistance is rising as well, making levofloxacin based salvage regimens less reliable. Amoxicillin and tetracycline resistance remain low globally (typically under 2 to 3%), which is why knowing your strain's resistance profile allows your clinician to construct a regimen with the highest chance of eradicating the infection on the first attempt.

How to Read Your Results Together

The real value of this panel is in reading the three categories of results as one picture. A positive H. pylori detection with multiple virulence markers and antibiotic resistance narrows your options and raises the stakes. A positive result with a low virulence profile and no resistance means treatment is straightforward and likely to succeed on the first try.

The virulence profile also helps frame long term surveillance decisions. If your strain carries cagA and babA but you successfully eradicate it, your gastroenterologist may still recommend periodic endoscopic screening depending on your family history and other risk factors, because the inflammatory damage may have already begun before treatment.

When Results Can Be Misleading

Proton pump inhibitors (PPIs), bismuth compounds, and antibiotics taken within two to four weeks before testing can suppress H. pylori below the detection threshold, producing a false negative result. If you are taking any of these medications, discuss timing with your clinician before collecting your sample. The American College of Gastroenterology (ACG) recommends stopping PPIs at least two weeks before H. pylori testing and antibiotics at least four weeks before.

Virulence gene detection reflects the dominant strain in your gut at the time of sampling. Mixed infections with multiple strains can occur, and a minor strain carrying resistance genes may not always be detected. A negative resistance result does not guarantee treatment success in every case, though it significantly improves the odds.

Tracking Over Time

The most important follow up test after H. pylori treatment is confirmation of eradication, ideally four to six weeks after completing your antibiotic course and at least two weeks off any PPI. If your initial panel showed a high virulence strain, confirming clearance is especially urgent. Persistent infection with a cagA positive, babA positive strain continues to drive the inflammatory cascade that raises cancer risk.

If first line treatment fails, retesting with a panel that includes resistance markers (rather than a simple yes/no antigen test) is the fastest path to a successful second attempt. Each failed treatment course increases the likelihood of acquiring additional resistance mutations, which makes getting it right early even more valuable.

What to Do with Your Results

If H. pylori is detected with any resistance markers, bring your full results to a gastroenterologist before starting treatment. Resistance guided therapy, where the antibiotic regimen is chosen based on your strain's specific vulnerabilities, achieves higher eradication rates than empiric therapy in clinical trials. The 2024 ACG guidelines now recommend susceptibility testing when it is available, particularly before prescribing clarithromycin based regimens.

If you test positive with a high virulence profile (cagA positive, babA positive, or multiple virulence genes detected), discuss with your clinician whether an upper endoscopy is warranted, especially if you are over 40, have a family history of gastric cancer, or have persistent upper abdominal symptoms. Successful eradication of H. pylori reduces gastric cancer risk, and earlier eradication provides greater benefit.

If your result is negative and you have ongoing symptoms such as bloating, upper abdominal pain, or unexplained iron deficiency, consider testing for other causes. A broader stool analysis or celiac panel may be the appropriate next step.